Lercadip

Lercanidipine hydrochloride, the active ingredient in Lercadip, is a calcium channel blocker presented as an oral formulation for oral use. It is indicated for the treatment of hypertension in adult patients. GNH USA supplies Lercadip as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercadip belongs to the calcium channel blocker class and is used to manage elevated blood pressure.

- Hypertension: lowers elevated blood pressure, helping to reduce the risk of cardiovascular events.

Lercadip may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Flushing: sensation of warmth and redness, especially of the face. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: light‑headed feeling, particularly when standing quickly. - Fatigue: general tiredness without exertion. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or swelling of the face and throat. - Angioedema: rapid swelling of deeper skin layers. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy with Lercadip, several safety considerations should be observed. - Blood pressure monitoring: regularly assess to ensure therapeutic targets are met. - Liver function: evaluate hepatic status, especially in patients with known liver disease. - Elderly patients: start at the lowest effective dose and monitor for orthostatic effects. - Concomitant antihypertensives: adjust doses to avoid excessive hypotension. - CYP3A4 inhibitors: avoid strong inhibitors that may raise drug levels. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercadip can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Other antihypertensives (e.g., ACE inhibitors, ARBs): risk of additive blood‑pressure lowering. - Grapefruit juice: can elevate drug levels and precipitate hypotension.

Moderate Interactions (Monitor Closely): - Other dihydropyridine calcium channel blockers: may produce additive vasodilatory effects. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response. - Beta‑blockers: may require dose adjustments to maintain hemodynamic stability.